ELVN (Enliven Therapeutics) Institutional Ownership: 88.97% (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELVN Enliven Therapeutics Inc ELVN
31 GF Score
Price $57.89
! 3 Warning Signs
View Full Analysis

What is Enliven Therapeutics Institutional Ownership?

Enliven Therapeutics ELVN -1.43% 31 Institutional Ownership is 88.97% as of Aug. 13, 2026. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Enliven Therapeutics's institutional ownership is 88.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Enliven Therapeutics's Insider Ownership is 0.55%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Enliven Therapeutics's Float Percentage Of Total Shares Outstanding is 69.40%.

Enliven Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Enliven Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enliven Therapeutics Institutional Ownership Chart

Enliven Therapeutics Historical Data

The historical data trend for Enliven Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 40.66 41.98 40.55 42.70 42.40 41.01 42.34 42.94 49.73 49.94
ELVN
31GF Score
Enliven Therapeutics Inc ELVN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enliven Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 88.97% mean?
Enliven Therapeutics (ELVN) has a Institutional Ownership of 88.97% as of Aug. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Enliven Therapeutics and its competitors.
Is Enliven Therapeutics' Institutional Ownership too high?
Enliven Therapeutics' current Institutional Ownership is 88.97%. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' Institutional Ownership compare to PBLS and CPRX?
Enliven Therapeutics' Institutional Ownership of 88.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Enliven Therapeutics and its competitors. Enliven Therapeutics's current Institutional Ownership is 88.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current Institutional Ownership of 88.97%. The current Institutional Ownership is 88.97%. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current Institutional Ownership is 88.97% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enliven Therapeutics Business Description

Address 6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score

Get the complete analysis for ELVN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.89
Price